NCT04481191View on ClinicalTrials.gov

Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)

PHASE3CompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

May 8, 2021

Study Completion Date

May 8, 2021

Conditions

Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

Interventions

BIOLOGICAL

RotaTeq (V260)

Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution

BIOLOGICAL

IPV

0.5 mL dose IPV (Sabin strain based), administered via IM injection

Trial Locations (1)

529600

Yangchun Center For Disease Prevention And Control ( Site 0001), Yangchun

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04481191 - Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074) | Biotech Hunter | Biotech Hunter